Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McMaster University

$35,136.00

Toxicant-induced resistance to ANOIKIS in estrogen sensitive target tissues

EF 2007-08

Résumé
Metastasis is a major factor in the malignancy of cancers. Anoikis (apoptosis resulting from loss of cell-matrix interactions) is thought to act as a physiological barrier to metastasis. Resistance to anoikis may allow survival of cancer cells in the systemic circulation and thus facilitate secondary tumor formation in distant organs. While contact free cell survival is a fundamental feature of metastasis in malignant cancers, we propose resistance to anoikis may also play a central role in the development of other diseases relevant to man and animals. For example, although a benign disease, endometriosis has many features in common with cancer cells including but not limited to: adhesion, invasion, neovascularization, and proliferation. However, the cause of endometriosis, an estrogen-dependent disease, is unknown. Of the different theories put forward, retrograde menstruation is the most widely accepted. Retrograde menstruation however occurs in approximately 90% of women whereas the prevalence of endometriosis is only between 10 and 14% of women of reproductive age. Therefore, factors other than retrograde menstruation of endometrial cells are likely important for these cells to survive and implant on pelvic structures, and proliferate. I therefore propose that in addition to being an important feature of cancer cell malignancy, resistance to anoikis is a key factor in the development of endometriosis. Moreover, I propose that environmental toxicants (ETs) can modulate anoikis and facilitate breast cancer cell survival and invasion. Several lines of evidence lend support to this novel proposal. In particular, down regulation of several pro-apoptotic and tumor suppressor genes has been revealed by cDNA microarray analysis of endometriotic tissue. In addition, apoptotic indices are significantly lower in endometrial cells from women with endometriosis compared to women without endometriosis. However, the mechanism(s) regulating cell survival following detachment from the basement membrane is not known. In a recent study, tyrosine kinase receptor B (TrkB), a neurotropic kinase receptor, has been shown to be a potent and specific suppressor of caspase-associated anoikis in non-malignant epithelial cells. Tyrosine kinases including TrkB are expressed in many tissues throughout the human body including epithelial cells of the breast, ovary, and endometrium. However, the mechanism(s) regulating TrkB expression in estrogen-dependent target tissues such as the breast and endometrium are unknown. In a series of preliminary studies, my laboratory has demonstrated that dieldrin treatment, an estrogenic pesticide, induces a dose-dependent increase in TrkB expression in MDA-MB-231 cells, an estrogen-independent invasive breast cancer cell line. Of note, we have also shown a dieldrin-induced increase in TrkB expression in MCF-7 cells, an estrogen-dependent non-invasive cell line. Treatment effects on cell survival, invasion, and response to an apoptotic signal have yet to be evaluated. In a separate set of preliminary experiments, we have shown that TrkB is expressed at higher levels in the endometrium of women with dysfunctional uterine bleeding and endometriosis compared to women without endometriosis. Therefore, we propose that toxicant-induced changes in TrkB expression are important in secondary tumor formation and facilitation of the survival of endometrial cells in menstrual effluent. Therefore, I hypothesize that ETs will increase TrkB expression (mRNA and protein) and will increase epithelial cell resistance to apoptosis in breast cancer and endometrial cells. I therefore predict that ET treatment will induce increased survival and invasion of breast cancer cell lines and endometrial epithelial cells in culture. To test this hypothesis two separate projects will be pursued. Project I: Breast cancer cell lines with different growth and tissue invasion characteristics will be treated with estradiol (E2), progesterone (P4), E2/P4, or dieldrin ± ICI 182,780 (an antiestrogen) or NS398 (a specific cyclooxygenase II inhibitor). TrkB expression (mRNA and protein), apoptosis, invasion, proliferation, and prostaglandin E2 will be measured by well established methods in my laboratory. These experiments will be repeated with K-252a a TrkB inhibitor. Project II:  Primary cultures of endometrial epithelial cells will be treated as above. Treatment effects on TrkB expression (mRNA and protein), proliferation and apoptosis will be measured. Successful completion of this project will define the mechanisms that regulate TrkB expression and demonstrate that toxicant-induced changes in TrkB are an important novel mechanism of endocrine toxicity. Results of this study will have wide reaching implications across the life sciences including toxicology, cancer biology, epidemiology, and regulatory toxicology.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
261905-2007
Name nom
Foster, Warren
Department département
Obstetrics and Gynecology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2007
Award amount
35136
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1011
Committee name en
Integrative Animal Biology
Committee name fr
Biologie Animale Intégrative
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5504
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal physiology and metabolism
Research subject fr
Physiologie et métabolisme des animaux
Partie
1
Nb partie
1
Application title
Toxicant-induced resistance to ANOIKIS in estrogen sensitive target tissues
Keyword
NA
Application summary
Metastasis is a major factor in the malignancy of cancers. Anoikis (apoptosis resulting from loss of cell-matrix interactions) is thought to act as a physiological barrier to metastasis. Resistance to anoikis may allow survival of cancer cells in the systemic circulation and thus facilitate secondary tumor formation in distant organs. While contact free cell survival is a fundamental feature of metastasis in malignant cancers, we propose resistance to anoikis may also play a central role in the development of other diseases relevant to man and animals. For example, although a benign disease, endometriosis has many features in common with cancer cells including but not limited to: adhesion, invasion, neovascularization, and proliferation. However, the cause of endometriosis, an estrogen-dependent disease, is unknown. Of the different theories put forward, retrograde menstruation is the most widely accepted. Retrograde menstruation however occurs in approximately 90% of women whereas the prevalence of endometriosis is only between 10 and 14% of women of reproductive age. Therefore, factors other than retrograde menstruation of endometrial cells are likely important for these cells to survive and implant on pelvic structures, and proliferate. I therefore propose that in addition to being an important feature of cancer cell malignancy, resistance to anoikis is a key factor in the development of endometriosis. Moreover, I propose that environmental toxicants (ETs) can modulate anoikis and facilitate breast cancer cell survival and invasion. Several lines of evidence lend support to this novel proposal. In particular, down regulation of several pro-apoptotic and tumor suppressor genes has been revealed by cDNA microarray analysis of endometriotic tissue. In addition, apoptotic indices are significantly lower in endometrial cells from women with endometriosis compared to women without endometriosis. However, the mechanism(s) regulating cell survival following detachment from the basement membrane is not known. In a recent study, tyrosine kinase receptor B (TrkB), a neurotropic kinase receptor, has been shown to be a potent and specific suppressor of caspase-associated anoikis in non-malignant epithelial cells. Tyrosine kinases including TrkB are expressed in many tissues throughout the human body including epithelial cells of the breast, ovary, and endometrium. However, the mechanism(s) regulating TrkB expression in estrogen-dependent target tissues such as the breast and endometrium are unknown. In a series of preliminary studies, my laboratory has demonstrated that dieldrin treatment, an estrogenic pesticide, induces a dose-dependent increase in TrkB expression in MDA-MB-231 cells, an estrogen-independent invasive breast cancer cell line. Of note, we have also shown a dieldrin-induced increase in TrkB expression in MCF-7 cells, an estrogen-dependent non-invasive cell line. Treatment effects on cell survival, invasion, and response to an apoptotic signal have yet to be evaluated. In a separate set of preliminary experiments, we have shown that TrkB is expressed at higher levels in the endometrium of women with dysfunctional uterine bleeding and endometriosis compared to women without endometriosis. Therefore, we propose that toxicant-induced changes in TrkB expression are important in secondary tumor formation and facilitation of the survival of endometrial cells in menstrual effluent. Therefore, I hypothesize that ETs will increase TrkB expression (mRNA and protein) and will increase epithelial cell resistance to apoptosis in breast cancer and endometrial cells. I therefore predict that ET treatment will induce increased survival and invasion of breast cancer cell lines and endometrial epithelial cells in culture. To test this hypothesis two separate projects will be pursued. Project I: Breast cancer cell lines with different growth and tissue invasion characteristics will be treated with estradiol (E2), progesterone (P4), E2/P4, or dieldrin ± ICI 182,780 (an antiestrogen) or NS398 (a specific cyclooxygenase II inhibitor). TrkB expression (mRNA and protein), apoptosis, invasion, proliferation, and prostaglandin E2 will be measured by well established methods in my laboratory. These experiments will be repeated with K-252a a TrkB inhibitor. Project II:  Primary cultures of endometrial epithelial cells will be treated as above. Treatment effects on TrkB expression (mRNA and protein), proliferation and apoptosis will be measured. Successful completion of this project will define the mechanisms that regulate TrkB expression and demonstrate that toxicant-induced changes in TrkB are an important novel mechanism of endocrine toxicity. Results of this study will have wide reaching implications across the life sciences including toxicology, cancer biology, epidemiology, and regulatory toxicology.